CN1530119A - Composition containing shelled buckwheat kernel extractive and use thereof - Google Patents
Composition containing shelled buckwheat kernel extractive and use thereof Download PDFInfo
- Publication number
- CN1530119A CN1530119A CNA031157726A CN03115772A CN1530119A CN 1530119 A CN1530119 A CN 1530119A CN A031157726 A CNA031157726 A CN A031157726A CN 03115772 A CN03115772 A CN 03115772A CN 1530119 A CN1530119 A CN 1530119A
- Authority
- CN
- China
- Prior art keywords
- shelled buckwheat
- extract
- compositions
- shelled
- shells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A process for biologically extracting the composite substance rich in protein, D-chiro-inositrol (D-CI) and total flavones of buckwheat (TEB) from the shelled and germinated buckwheat, the composition of said extract and 1-deoxynojirimycin (DNJ), and the application of said composition in preparing the medicines for preventing and treating diabetes are disclosed.
Description
Technical field:
Diabetes of the present invention field, relate in particular to a kind of Semen Fagopyri Esculenti, relate in particular to a kind of compositions that from the shelled buckwheat after the rudiment of shelling, obtains the preparation method of extract and contain this extract, and the application in the product of this compositions in preparation prevention and treatment diabetes.
Background technology:
Diabetes (Diabetes mellitus) are to be a kind of syndrome of feature to continue hyperglycemia.Its Pathophysiology mainly is because insulin active is relative or absolute not enough.
Insulin is the hormone that is produced by the islets of langerhans organ, acts on human body vitals and perienchyma's regulation and control sugar, fat and other metabolic process after entering blood circulation.Insulin is incorporated into the human cell surface receptor protein, activates a series of signal pipeline, causes the cell surface channel to be opened, and glucose in the blood is introduced in the cell, thereby reached blood sugar reducing function.Any step is obstructed or efficient reduces and all can cause insulin action malfunctioning in this signal pipeline, i.e. insulin resistance.Insulin resistant is a kind of unusual pathological and physiological condition, and the mechanism of its generation is divided three classes: factor before (1) Insulin receptor INSR.Comprise that 1. the insulin gene sudden change produces cacoplastic insulin, its biological activity descends or forfeiture; 2. endogenous or exogenous insulin antibody form, and interfere with insulin combines with the normal of receptor; 3. insulin receptor antibody forms, and disturbs and its receptors bind; 4. the insulin degraded is quickened.(2) receptor defects descends and the Insulin receptor INSR textural anomaly as Insulin receptor INSR decreased number, insulin affinity.(3) postreceptor defects, refer to insulin and receptors bind after signal in cell, transmit caused a series of metabolic process.Comprise that 1. glucose transporter is proteic unusual; 2. glucose phosphorylation obstacle in the cell; 3. mitochondrion oxidative phosphorylation obstacle; 4. free fatty increases, and glycogen output and output increase; 5. tumor necrosis factor (TNF-a) effect (modern diabetology, climax peace etc., 2000:41).For compensation insulin action efficient reduces, human body produces more insulin.Continue hyperinsulinism concentration in the blood and cause metabolism disorder, diseases such as blood sugar increasing.
(impaired glucose tolerence, IGT) patient are prediabetes state crowds to impaired glucose tolerance, and its fasting glucose is normal, and post-prandial glycemia is higher unusually, and it is high 100 times than the ordinary people that this class patient is converted into the diabetes probability.IGT crowd can reduce conversion to diabetes by long-term pharmaceutical intervention.
Diabetes can't be effected a radical cure at present, and most diabeticss are kept blood glucose normally or normal substantially by taking medicine for a long time.Blood glucose is normal, comprises two indexs of post-prandial glycemia and fasting glucose usually.
Semen Fagopyri Esculenti is a kind of traditional food useful to diabetes of China.China has the patents of 200 multinomial relevant buckwheat foods now, all is based on the compound product of threpsology's mechanism or theory of Chinese medical science.For a long time, (Total flavones of buckwheat TFB) is acknowledged as active factors in the Semen Fagopyri Esculenti to flavonoid.The flavonoid of Semen Fagopyri Esculenti mainly comprises rutin, Quercetin, flavonol etc., and the phenolic hydroxyl group that contains in the flavonoid is antioxidant groups (Chinese Pharmacological Bulletin, 2001Dec; 17 (6)).The Quercetin that Semen Fagopyri Esculenti contains can suppress the alditol reductase, and the effect of Profilin nonenzymatic glycosylation improves antioxidant ability of organism, thereby diabetes and complication are had preventive and therapeutic effect (work medical science 18 2 phases of volume of April calendar year 2001).It improves carbohydrate metabolism, be commonly considered as the effect of para-insulin sample and (or) increase the sensitivity of peripheral tissues to insulin.
The further investigation in many years of seed scientist Obendorf of U.S. cornell university is found also to contain another kind of functional factor D-chirality-inositol (D-Chiro-Inositol, D-CI) monomer and D-CI derivant in Fagopyrum (Fagopyrum) plant seed.The D-CI derivant is that D-CI and 1～3 galactose are with the bonded one group of glycoside compound of α glycosidic bond.According to U.S. scientist research in recent years, prove that D-CI has played the part of the key player in the insulin signaling transmittance process.Its mechanism of action is such: D-CI is the ingredient of insulin active amboceptor (insulin mediator) in cell.As amboceptor, it promotes the dephosphorylation of Glycogensynthase and pyruvic dehydrogenase, and these two kinds of enzymes are glucose oxidase and non-oxide rate-limiting enzyme (Int J Exp Diabetes Res 2002; 3 (1): 47-60).In a word, D-CI works in the downstream of insulin signaling transmission.Discover in the normal human blood and urine in contain certain density D-CI, then almost detect among the diabetes patient less than, point out these patients possibly can't produce the D-CI of q.s, cause the signal transduction process of insulin action to be obstructed.A large amount of tests confirm that D-CI can effectively promote insulin function, blood sugar lowering, blood insulin, blood triglyceride level to the animal compensation.Give D-CI and can significantly improve the human body abnormal glucose tolerance.
According to U.S. USP6162795, in the exsiccant buckwheat seed of maturation, embryo (embryo) and aleurone (aleurone) have comprised D-CI and D-CI derivant thereof all in the seed.
The distribution position of protein, TFB, D-CI and D-CI derivant thereof and content are as table 1:(Minn-Dak Growers, Ltd.Highway 81 North, PO Box 13276, Grand Forks ND 58208,2002 years in the ripe buckwheat seed).
Table 1 is the active component in the rudiment Semen Fagopyri Esculenti not
mg/100g
| The composition title | The Semen Fagopyri Esculenti furfur | Shelled buckwheat | Buckwheat seed |
| Protein | ???35～44 | ????12.3 | ????12.3 |
| Flavone | ???47 | ????7.1 | Trace |
| ????D-CI | ???1371 | ????287 | Trace |
| The D-CI derivant | ???2600 | ????565 | ????128 |
If without any pretreatment, directly water carries out extracting to Semen Fagopyri Esculenti furfur, shelled buckwheat, the buckwheat seed of not rudiment, and the D-CI content of monomer is few in the extract of gained, is respectively 1.3%, 0.29% and trace (as table 1).And, be a mixture based on sugar.
To containing the highest not rudiment Semen Fagopyri Esculenti furfur extracting of D-CI amount of monomer, sucrose accounts for 55% of soluble sugar in the extract.(J?Agric?Food?Chem?2000?Jul；48(7)：2843-7)
Research finds that also (P28 USP6162795), does not contain in the human body the intestines and stomach and can cut off alpha-galactose-glycoside key, the monomeric alpha-galactosidase of release D-CI.In the buckwheat seed naturally occurring D-CI derivant only at Di by bacterial digestion, discharge the D-CI monomer.Therefore, if direct edible buckwheat, its blood sugar regulation has little effect.
Domestic and foreign literature (USP6162795:P22, Food ﹠amp; Fermentation Industries 1990No.2 etc.) all having disclosed germination can make plant seed discharge alpha-galactosidase.Obtain the monomeric numerous technical methods of D-CI by Semen Fagopyri Esculenti is germinateed, have following common feature:
(1) utilizes the complete buckwheat seed that contains shell (pericarp), and there is no D-CI and derivant thereof in the Buckwheat shell (pericarp).
(2) buckwheat seed (all containing shell pericarp) of rudiment or not rudiment is pulverized, after the homogenized, the ethanol/water extracting of reuse finite concentration ratio.Its result makes to account for the starch of buckwheat seed more than 70%, and a large amount of solubility monosaccharide, the disaccharidase key component that becomes final extract.In fact, occupying the most endosperm of Semen Fagopyri Esculenti central authorities almost all is starch.Yet diabetics or IGT crowd's eating patterns should be low sugar high proteins.
Folium Mori are the another kind of medicine-food two-purpose food useful to diabetes.Shanghai Fudan Zhangjiang biomedical Co., Ltd after deliberation, the Folium Mori nojirimycin (DNJ) that extracts from Folium Mori can effectively suppress alpha-galactosidase, control post-prandial glycemia rising.(referring to Chinese patent literature: number of patent application: 01113191.8).
Summary of the invention:
The object of the present invention is to provide a kind of shelled buckwheat extract that shells.
The objective of the invention is to set up a kind of efficient, economic and easy process, fully extracting D-CI, TFB and proteinic while in the buckwheat seed, control the stripping of diabetes such as starch, sucrose and the incompatible glucide of IGT patient again to greatest extent, and join by the excellent of D-CI, TFB, DNJ, obtain many target spots of functional factor tool action site, the nourishing healthy product of coordinated regulation post-prandial glycemia and fasting glucose.
The present invention obtains the monomeric shelled buckwheat of high-load D-CI and is achieved in that the shelled buckwheat that uses after sophisticated the shelling at 15 ℃～35 ℃, soaks through 0.5～6hr clean water, and moisture state is sprouted 12～48hr down.Preferably, the shelled buckwheat after use is shelled soaks through the 1hr clean water at 20 ℃, and moisture state is sprouted 20hr down.
D-CI derivant in the shelled buckwheat seed that the process said method was handled reduces significantly, and the monomeric content of D-CI significantly increases.At 20 ℃, soak through the 1hr clean water, after moisture state was sprouted 20hr down, the monomeric content of D-CI reached 79.6mg/g, and more the D-CI content of monomer 2.87mg/g in the shelled buckwheat of rudiment has not improved 28 times.
The preparation method that from shelled buckwheat, obtains extract of the present invention, the step that comprises is:
1.. adopt the shelled buckwheat after the above-mentioned described sprouting, 5～10 times solid-liquid ratio (kg/L) of dry weight before pressing shelled buckwheat and sprouting adds 40～60% ethanol, and the shelled buckwheat after sprouting is carried out extracting;
2.. before the extracting shelled buckwheat of this sprouting without mill, homogenized.
3.. extract concentrates after filtration and/or centrifugal, and drying obtains the extract of rich in proteins, D-CI and TFB.
Another object of the present invention is to provide a kind of compositions that contains the shelled buckwheat extract, described compositions comprises shelled buckwheat extract and Folium Mori nojirimycin, wherein in described compositions, contain nojirimycin 0.1～99%, D-chirality-inositol 0.1～30%, flavonoid 0.1～20% protein 0.1～50%, wherein, total sugar content is between 20-30%.Preferably, in described compositions, contain DNJ 2.1%, D-CI 2.0%, and TFB 1.5%, protein 32%, and wherein, total sugar content is 30%.
Another object of the present invention is to provide the application of the compositions that contains the shelled buckwheat extract that shells in the product of preparation prevention or treatment diabetes.
With shelled buckwheat extract and Folium Mori DNJ composite after, the acceptor site difference of functional factors such as the D-CI that contains in the compositions that obtains, TFB, DNJ.The receptor of DNJ is at the intestinal brush border cell, onset rapidly after the meal, and it is obvious to suppress post-prandial glycemia; The receptor of D-CI and TFB works in the process of insulin signaling transmission then at liver and muscle cell, and produce effects is slow and lasting.Theoretically, the combination of D-CI, TFB and DNJ has the effect of Collaborative Control blood glucose.
Zoopery and clinical experiment show that complex composition of the present invention has tangible blood sugar reducing function to diabetic mice and diabetics.Complex composition blood sugar lowering effect becomes positive correlation with the total amount of D-CI, TFB, DNJ wherein, and D-CI, TFB or DNJ monomer blood sugar lowering effect than isodose are better, all produce effect to suppressing post-prandial glycemia and fasting glucose, functional factor has cooperative effect in the prompting compound on hypoglycemic activity.
The dosage form that contains the compositions of shelled buckwheat extract of the present invention can be any dosage form of approving on pharmaceutics and the bromatology, include but not limited to this compositions and with the capsule of making after pharmacy or acceptable auxiliary are mixed, tablet, granule, suspension, oral liquid etc.Suitable dose of the present invention is absorbed 300mg～3600mg compositions with per day for adults and is advisable.
Antihypelipidemic foodstuff in the present invention and the prior art is compared:
(1) raw material science.Being enriched in architectural feature in aleurone and the embryo according to protein, D-chirality-inositol and flavonoid in the Semen Fagopyri Esculenti, is the extracting raw material with the rudiment shelled buckwheat scientifically.The shelled buckwheat raw material can directly large quantities ofly from the market be buied.
(2) technology is efficient, easy, economical.Fully and dexterously take into account the physicochemical property of functional factor D-CI and TBF and the architectural feature of seed.The not broken not homogenate of rudiment shelled buckwheat is not stirred in the extractive process, and extract is pressed in infiltration cycles between wheat grain by pound and causes relative motion between raw material and solvent.Work simplification, effect improves more than 50%.
(3) extract trophism and functional having both: what use the present invention obtained is a kind of abundant extract of low sugar high protein, functional factor D-CI and TBF of uniqueness.Compare with the extract that other technologies obtain, total sugar significantly reduces (range of decrease is more than 100%), and total protein significantly improves (amplification is more than 200%), and the content and the ratio of functional factor are excellent.
(4) the compound effect is remarkable: functional factor D-CI, the TFB, the DNJ action target spot that extract in shelled buckwheat and the Folium Mori are different, onset time difference, all produce effect to suppressing post-prandial glycemia and fasting glucose, show the effect of coordinated regulation blood glucose.
The specific embodiment:
Embodiment 1:
The method of the monomeric rudiment shelled buckwheat of D-CI is rich in a kind of preparation
Material requirements: the above ripe buckwheat seed of 24～28 DPA (pollination day), behind the removal achene shell (pericarp), the wheat core granule is complete substantially.
Shelled buckwheat 50 grams that shell use drinking public water supply, behind 20 ℃ of immersion 24hr, are tiled on the moistening gauze, and cover gauze, and 20 ℃ keep moistening 24hr down, and bud reaches 0.5～1.0cm, D-CI content 79.6mg/g.
Embodiment 2:
The method of the monomeric rudiment shelled buckwheat of D-CI is rich in large-scale production
The sophisticated shelled buckwheat 200kg that shells uses drinking public water supply, behind 20 ℃ of immersion 1hr, is tiled on the moistening straw mat, and 1～30 seed stack of thickness covers straw mat, keeps moistening 24hr, and bud reaches 0.5～1.0cm, D-CI content 29.8mg/g.
Embodiment 3:
D-CI monomer, TFB and method for producing protein in the extensive extraction shelled buckwheat
Concrete steps are as follows:
1. the shelled buckwheat 200kg that shells, drinking public water supply soaks 1hr for 20 ℃, and accelerating germination 24hr on the moistening straw mat gets the rudiment shelled buckwheat that bud is about 0.8cm.
2. in the extraction pot (the tank bottoms 100 order nets that cover) of 3000L, inject the ethanol 2000L of food stage 50%, again impouring 200kg rudiment shelled buckwheat.The ON cycle pump permeates and mistake extract ethanol between wheat grain.Extracting 2hr like this under 30 ℃ emits extract.Extracting once more under the equal conditions merges the secondary extract.Concentrate through evacuation earlier and remove ethanol, volume is to 300L, again through 15, and the 000g continuous flow centrifugation, the supernatant evacuation is concentrated into 80L.The concentrated solution spray drying gets 8.0kg dry powder, D-CI content of monomer 28.2mg/g, TBF 2.6mg/g, protein 232mg/g.
Embodiment 4:
The extracting method that Folium Mori DNJ extracts
Folium Mori 1000g adds water 10L, and soaked overnight is boiled back 95 ℃ of insulation 2hr, filters.Filtering residue adds 8L water again, boils back 95 ℃ of insulation 2 hr, filters.Merge filtrate twice, concentrate, flocculation, centrifugal.Centrifugal back clear liquid is crossed Amberlite IR120C cation exchange column, with 0.5N ammonia spirit eluting, collects and goes up 201 * 7 anion-exchange columns again after liquid concentrates, and collects not absorbed portion, concentrates, and drying gets the 10g total alkaloids, wherein contains DNJ 1g.
Embodiment 5:
Preparation contains the method for compositions of shelled buckwheat extract and Folium Mori DNJ
1. shelled buckwheat 200kg, drinking public water supply soaks 2hr for 18 ℃, accelerating germination 30hr on the moistening straw mat, the rudiment shelled buckwheat.
2. in the extraction pot (the tank bottoms 100 order nets that cover) of 3000L, inject food stage 50% ethanol 2000L, impouring 200kg rudiment shelled buckwheat again.The ON cycle pump permeates and mistake extract ethanol between wheat grain.Extracting 2hr like this under 30 ℃ emits extract.Extracting once more under the equal conditions merges the secondary extract.Concentrate through evacuation earlier and remove ethanol, volume is to 300L, again through 15, and the 000g continuous flow centrifugation, the supernatant evacuation is concentrated into 70L, and is standby.
3. Folium Mori 100kg, pure water 1000L soaked overnight, boiling water extraction 2hr filters.Extract altogether three times, merge three times filtrate, heat is concentrated into 11L, and is standby.
4. with the 11L extract of step 3, reach food stage magnesium stearate 291g, sneak into the 70L concentrated solution of step 2 in the lump, mixing is crossed 60 order nets.Filtrate is through centrifugal materialization device, and the 20L/h spray drying gets 8.85kg dry powder.
This dry powder is the compositions of shelled buckwheat extract and Folium Mori DNJ, has the blood sugar regulation effect, can be made into the health food of capsule, tablet, granule, suspension, oral liquor and other types of formulations, and is used to prevent and improve other products of diabetes.
Embodiment 6:
Table one is that the inventor entrusts hospital, according to Ministry of Public Health human experiment experiment rules, to fasting glucose 〉=7.8mmol/L or 7.8～6.1mmol/L; 2hr blood glucose 〉=11.1mmol/L or 10 diabeticss between 11.1mmol/L～7.8mmol/L give complex composition of the present invention after the meal, 1800mg/ days, take 15 days continuously after, the changing condition of fasting glucose and post-prandial glycemia.
The compositions of table one shelled buckwheat extract and Folium Mori DNJ is to the hypoglycemic activity of diabetics
| Case number | 0 day FBG (mmol/L) | 15 days FBG (mmol/L) | 0 day PG (mmol/L) | 15 days PG (mmol/L) |
| ????1 | ?9.5 | ?8.6 | ?14.6 | ?11.2 |
| ????2 | ?8.0 | ?7.0 | ?11.6 | ?10.9 |
| ????3 | ?7.9 | ?9.0 | ?11.0 | ?11.0 |
| ????4 | ?8.1 | ?7.1 | ?10.8 | ?9.6 |
| ????5 | ?9.7 | ?7.8 | ?10.4 | ?9.1 |
| ????6 | ?9.8 | ?8.8 | ?16.7 | ?11.5 |
| ????7 | ?6.7 | ?7.2 | ?13.2 | ?11.4 |
| ????8 | ?7.8 | ?6.7 | ?12.7 | ?10.9 |
| ????9 | ?9.9 | ?7.7 | ?15.0 | ?8.3 |
| ????10 | ?9.3 | ?8.8 | ?9.3 | ?8.0 |
Annotate: FBG: fasting glucose PG: post-prandial glycemia
Embodiment 7:
Table two is to use the statistical disposition result of SPSS software to subordinate list one fasting glucose and post-prandial glycemia, shows that the compositions of shelled buckwheat extract and Folium Mori DNJ can significantly reduce fasting glucose P＜0.05, extremely significantly reduces post-prandial glycemia P＜0.01.
Table two SPSS software his-and-hers watches-FBG and PG statistical disposition result
| The pairing sample | Pairing sample difference value | The t value | Degree of freedom | The P value | ||||
| Average | Standard deviation | Standard error | 95% fiducial limit | |||||
| Lower limit | The upper limit | |||||||
| ??FBG0--FBG15 | ?.800 | ?.9877 | ??.3123 | ??.093 | ??1.507 | ?2.561 | ????9 | ??.031 |
| ??PG2H0--PG2H15 | ?2.340 | ?2.1219 | ??.6710 | ??.822 | ??3.858 | ?3.487 | ????9 | ??.007 |
Embodiment 8:
Table three be the inventor with reference to Ministry of Public Health " the health food function assessment assessment process and the method for inspection ", give the compositions of shelled buckwheat extract and Folium Mori DNJ to diabetes ICR mice, dosage 125～1000mg/kg days, the fasting glucose changing condition after continuous 15 days.
Table four is dosage designs of each experimental group.
The compositions of table three shelled buckwheat extract and Folium Mori DNJ is to the effect of diabetes ICR mice fasting glucose
| The dosage group | ????????????????????????FBG(mmol/L) | ||||||
| ?MC | ?20.8 | ?22.0 | ?25.7 | ?16.1 | ?19.2 | ?22.8 | ?/ |
| ?L1 | ?21.2 | ?20.6 | ?23.6 | ?21.8 | ?19.2 | ?22.2 | ?/ |
| ?L2 | ?14.1 | ?16.1 | ?24.7 | ?9.2 | ?19.8 | ?17.1 | ?/ |
| ?M | ?5.6 | ?11.1 | ?4.5 | ?8.6 | ?9.0 | ?12.6 | ?/ |
| ?H | ?6.7 | ?4.7 | ?7.5 | ?6.4 | ?5.6 | ?10.5 | ?/ |
| ?PC | ?4.0 | ?10.7 | ?4.5 | ?8.2 | ?4.9 | ?12.8 | ?8.3 |
Annotate: the contrast of MC-mould, L1-lowest dose level group, L2-low dose group, dosage group among the M-, H-high dose group, PC-positive control
The compound concentration of each dosage group of table four table three and D-CI content
Embodiment 9:
Table five is to use SPSS software to subordinate list three fasting glucose statistical disposition results, the compositions that shows shelled buckwheat extract and Folium Mori DNJ is effective to reducing blood glucose in diabetic mice, and amount effect relationship, when the complex composition dose reaches 250mg/kg, can significantly reduce diabetic mice fasting glucose P＜0.05.Table five shows that also the pure product D-CI (positive controls) of equal D-CI dosage and complex composition (high dose group) are aspect reduction diabetes ICR mice fasting glucose, and the latter's effect is stronger.Show in the complex composition of the present invention the collaborative blood sugar reducing function of tool between each functional factor.
Table five SPSS software his-and-hers watches three FBG statistical disposition results
| The pairing sample | Pairing sample difference value | The t value | Degree of freedom | The P value | ||||
| Average | Standard deviation | Standard error | 95% fiducial limit | |||||
| Lower limit | The upper limit | |||||||
| ????MC-L1 | ??-.333 | ??2.782 ????6 | ????1.136 ??????0 | ???-3.253 | ??2.587 | ??-.293 | ????5 | .781 |
| ????MC-L2 | ??4.267 | ??3.222 ????8 | ????1.315 ??????7 | ??.885 | ??7.649 | ??3.243 | ????5 | .023 |
| ????MC-M | ??12.53 ????3 | ??4.921 ????7 | ????2.009 ??????3 | ??7.368 | ??17.69 ????8 | ??6.238 | ????5 | .002 |
| ????MC-H | ??14.20 ????0 | ??3.157 ????2 | ????1.288 ??????9 | ??10.88 ????7 | ??17.51 ????3 | ??11.01 ????7 | ????5 | .000 |
| ????MC-PC | ??13.58 ????3 | ??4.883 ????2 | ????1.993 ??????6 | ??8.459 | ??18.70 ????8 | ??6.814 | ????5 | .001 |
Claims (10)
1, a kind of compositions that contains the shelled buckwheat extract that shells is characterized in that: described compositions comprises shelled buckwheat extract and Folium Mori nojirimycin.
2, a kind of compositions that contains the shelled buckwheat extract that shells as claimed in claim 1, it is characterized in that: in described compositions, contain nojirimycin 0.1～99%, D-chirality-inositol 0.1～30%, flavonoid 0.1～20%, protein 0.1～50%, wherein, total sugar content is between 20-30%.
3, a kind of compositions that contains the shelled buckwheat extract that shells as claimed in claim 2 is characterized in that: in described compositions, contain nojirimycin 2.1%, D-chirality-inositol 2.0%, flavonoid 1.5%, protein 32%, wherein, total sugar content is 30%.
4, the described shelled buckwheat extract that shells of claim 1, it is characterized in that: described extract is prepared by following method:
A) shelled buckwheat after use is shelled soaks through 0.5～6hr clean water at 15 ℃～35 ℃, and moisture state is sprouted 12～48hr down;
B) press 5～10 times the solid-liquid ratio (kg/L) that shelled buckwheat is sprouted preceding dry weight, use 40～60% ethanol, the shelled buckwheat after sprouting is carried out extracting;
C) before the extracting shelled buckwheat of this sprouting without mill, homogenized;
D) extract concentrates after filtration and/or centrifugal, and drying obtains the extract of rich in proteins, D-chirality-inositol and flavonoid.
5, shelled buckwheat extract as claimed in claim 4 is characterized in that: in described step a, the temperature that the shelled buckwheat after shelling soaks is 20 ℃.
6, shelled buckwheat extract as claimed in claim 4 is characterized in that: in described step a, the time that the shelled buckwheat after shelling soaks is 1hr.
7, shelled buckwheat extract as claimed in claim 4 is characterized in that: in described step a, the shelled buckwheat after shelling is sprouted 20hr under moisture state.
8, the described application of compositions in the product of preparation prevention or treatment diabetes that contains the shelled buckwheat extract that shells of claim 1.
9, the application of compositions in the product of preparation prevention or treatment diabetes that contains the shelled buckwheat extract that shells as claimed in claim 8 is characterized in that: in described compositions, add pharmaceutically or acceptable auxiliary on the bromatology.
10, contain the application of compositions in the product of preparation prevention or treatment diabetes of the shelled buckwheat extract that shells as claimed in claim 8 or 9, it is characterized in that: the dosage form of described compositions is any dosage form of approving on pharmaceutics and the bromatology.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031157726A CN1530119A (en) | 2003-03-13 | 2003-03-13 | Composition containing shelled buckwheat kernel extractive and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031157726A CN1530119A (en) | 2003-03-13 | 2003-03-13 | Composition containing shelled buckwheat kernel extractive and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1530119A true CN1530119A (en) | 2004-09-22 |
Family
ID=34284432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031157726A Pending CN1530119A (en) | 2003-03-13 | 2003-03-13 | Composition containing shelled buckwheat kernel extractive and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1530119A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904907B (en) * | 2009-06-03 | 2012-04-18 | 上海诺金科生物科技有限公司 | Buckwheat extract abundant in inositol and general flavone and preparation method thereof |
| CN102976900A (en) * | 2012-10-13 | 2013-03-20 | 内蒙古清谷新禾有机食品集团有限责任公司 | Method for extracting and enriching chiral inositol from buckwheat brans |
| CN106901358A (en) * | 2016-12-28 | 2017-06-30 | 内蒙古医科大学 | A kind of health food with regulation blood sugar and prevention diabetic complication effect |
-
2003
- 2003-03-13 CN CNA031157726A patent/CN1530119A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101904907B (en) * | 2009-06-03 | 2012-04-18 | 上海诺金科生物科技有限公司 | Buckwheat extract abundant in inositol and general flavone and preparation method thereof |
| CN102976900A (en) * | 2012-10-13 | 2013-03-20 | 内蒙古清谷新禾有机食品集团有限责任公司 | Method for extracting and enriching chiral inositol from buckwheat brans |
| CN106901358A (en) * | 2016-12-28 | 2017-06-30 | 内蒙古医科大学 | A kind of health food with regulation blood sugar and prevention diabetic complication effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1257724C (en) | Composition for preventing and treating diabets mellitus | |
| CN101023967B (en) | Compound extract of common phellinus fungus and chaga, its preparing method and preparation | |
| CN1939418A (en) | Chinese medicinal herb composition with food and medicine consangunity | |
| CN1250246C (en) | Medicinal mixture possessing alpha glycocidase inhibiting activity and its use | |
| CN106036420A (en) | Tartary buckwheat health care food applicable to diabetics and preparation method thereof | |
| CN1723981A (en) | Novel use of extractive of Momordica grosvenori as adjuvant drug for preparing medicine | |
| CN1394623A (en) | Health-care food capable of regulating blood sugar and preparing method thereof | |
| CN100344642C (en) | Process for preparing flaxseed lignan total glycoside extract and use thereof | |
| CN110772630A (en) | Compound bitter gourd peptide oral liquid for activating insulin receptor and regulating blood sugar and preparation method thereof | |
| KR20120003693A (en) | Anti-obesity composition comprising red grape extracts, green tea extracts, soybean extracts, and l-carnitine | |
| CN1224329C (en) | Feed additive made of herbal medicine compound concentrate, and its prepn. method | |
| CN1602758A (en) | Nutritious liquor (drink) for relieving the effect of alcohol, alcohol relieving capsule production method | |
| CN1143681C (en) | Medicinal composition for diabetes | |
| CN1709342A (en) | Multiflower knotweed tuber prepared product and its preparing method | |
| CN101283799A (en) | Preparation method of health food for adjusting the blood fat | |
| CN1901927A (en) | Alpha-glucosidase activity inhibitor | |
| CN1136931A (en) | Ant ginseng oral liquid and preparing process thereof | |
| CN115337331B (en) | Preparation method of antidiabetic Chinese holly She Gutai fermented product and liquid fermented product | |
| CN1530119A (en) | Composition containing shelled buckwheat kernel extractive and use thereof | |
| CN102940650A (en) | Propolis ethanol extract for dispeling the effects of alcohol, preparation method of propolis ethanol extract and application of propolis ethanol extract for producing enteric-coated tablets | |
| CN1861104A (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN1061537C (en) | Monascus preparation for hyperlipemia and relevant cardiac and cerebral diseases | |
| CN1864545A (en) | Preparation of highland barley SOD an conditioning food containing highland barley SOD | |
| CN1884503A (en) | Bamboo leaf SOD preparation and functionalized food containing bamboo leaf SOD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |